$ABSI

Absci Corporation (ABSI) announced plans for a Phase 2 trial of ABS-201, an AI-designed antibody for endometriosis, expected to start in mid-2027. The trial will assess efficacy and safety in 150 patients across 10 countries, focusing on pain reduction. ABS-201 targets the prolactin receptor, offering a non-hormonal approach to treatment.

Vicor Corp (VICR) shares rose 13.5% to $208.73 after granting a license for its patents. Other stocks gaining include Securitize (SECZ) +21%, Generac (GNRC) +19.6%, and Arm (ARM) +6.7%. Generac's rise follows a supply deal with Amazon and a price target increase. Micron (MU) gained 5.6% amid a memory stock rally.

Veradermics (MANE) and Absci (ABSI) shares have surged as investors bet on the hair-loss drug market. Veradermics reported positive trial results for an oral minoxidil tablet, while Absci is developing an AI-designed injectable treatment. Both companies face competition and clinical risks, with no new FDA-approved hair-loss drug since the 1990s.

Absci (ABSI) reported Q2 2026 revenue of $0.3M, down from $0.6M in 2025, with a net loss of $33.2M. R&D expenses rose to $22.6M, driven by ABS-201 clinical progress. Cash increased to $201.1M, supported by a $100M financing round, including $40M from Eli Lilly. The company expects ABS-201 data in late 2026 and 2027, with Phase II endometriosis trials starting in Q4 2026. Management highlighted a 2028 cash runway and platform advancements.

Advanced Micro Devices (AMD) filed its first 13F, revealing a $1.31 billion portfolio with six positions. Top holdings include SpaceX, Absci (ABSI), Sanmina (SANM), Nutanix (NTNX), and Quantum Computing (QUBT). AMD's Q2 revenue surged 50.1% YoY to $11.536 billion, with data center revenue doubling. AMD expects Q3 revenue of $13 billion, citing strong AI demand.

Absci Corp shares fell 16.6% in after-hours after reporting Q2 2026 results. According to the company, revenue was $0.3M versus about $1.01M expected and down from $0.6M a year earlier. The per-share loss was $0.21 versus a $0.19 expected loss, with a $33.2M net loss. CEO cited Phase 1 HEADLINE trial interim data, but investors focused on the financial miss.

Absci Corp (ABSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly

Anthropic is reportedly targeting an IPO in September or early October 2026, according to the Wall Street Journal. In investor meetings, it said it plans to expand healthcare and biology AI use cases. The article highlights potential AI-biotech beneficiaries, citing results and guidance for Absci, Recursion, Schrodinger, Twist Bioscience, and Tempus AI, including Tempus Q2 revenue of $382.49M and raised FY guidance to $1.595 to $1.605B.

Szela Mary T purchased 12,900 shares of Absci Corp (ABSI) at $11.54 ($0.15M total) on 2026-06-30.

Absci Corp. (NASDAQ:ABSI) shares rose premarket Wednesday after HC Wainwright upgraded its outlook, raising the price target from $8.00 to $16.00 and keeping a buy rating. The stock closed at $7.41 and opened at $9.51. Other analysts set targets from $11 to $15. The move follows positive interim Phase 1 ABS-201 data and a $100 million underwritten offering.